Study of Adalimumab in Patients With Axial Spondyloarthritis
Public ClinicalTrials.gov record NCT00939003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate how well adalimumab works in the short and long term in patients with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.
Study identification
- NCT ID
- NCT00939003
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 192 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2009
- Primary completion
- Jan 31, 2011
- Completion
- Jul 31, 2013
- Last update posted
- Sep 8, 2014
2009 – 2013
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 21250 | Birmingham | Alabama | 35205 | — |
| Site Reference ID/Investigator# 21249 | Colorado Springs | Colorado | 80910 | — |
| Site Reference ID/Investigator# 21245 | Denver | Colorado | 80230 | — |
| Site Reference ID/Investigator# 21246 | Wheaton | Maryland | 20902 | — |
| Site Reference ID/Investigator# 26582 | Duncansville | Pennsylvania | 16635 | — |
| Site Reference ID/Investigator# 21241 | Wyomissing | Pennsylvania | 19610 | — |
| Site Reference ID/Investigator# 21243 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 21248 | Houston | Texas | 77030 | — |
| Site Reference ID/Investigator# 21247 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00939003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2014 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00939003 live on ClinicalTrials.gov.